<DOC>
	<DOCNO>NCT00496457</DOCNO>
	<brief_summary>The purpose study assess efficacy safety TRO19622 administer PO daily 6 week compare placebo administer PO daily patient painful peripheral diabetic neuropathy .</brief_summary>
	<brief_title>Efficacy Study With 500 mg QD TRO19622 v Placebo Patients With Painful Peripheral Diabetic Neuropathy</brief_title>
	<detailed_description>Diabetic peripheral neuropathic pain ( DPNP ) affect approximately 11 % patient diabetic peripheral neuropathy ( DPN ) . Diabetic neuropathy underlying disease common long-term complication diabetes mellitus estimate experienced majority patient least mild manner . Many patient ( DPNP ) respond adequately individual treatment option . None various treatment use consider cure . As result , although variety drug available treatment diabetic neuropathic pain , strong need develop new drug great efficacy and/or few adverse effect . The primary objective study compare effect TRO19622 versus placebo 24h neuropathic pain score last 7 day 6-week treatment period . Secondary objective compare efficacy neuropathic pain , impact emotional functioning , safety profile , pain time course , response rate TRO19622 versus placebo . Additionally , pharmacokinetics TRO19622 assess .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Be male &gt; 18 year postmenopausal female ( &gt; 60 year age least 1 year amenorrhea ) . Have painful diabetic neuropathy &gt; 6 month duration either pain treatment naive important side effect inadequate relief current pain medication . Be current pain medication ( prescribed analgesic ) , stable least 3 month study entry ( ± 25 % dosage basic pain medication , topup rescue medication allow ) , pain treatment naive . Have stable diabetes , define HbA1c &lt; 10 % , change medication previous 3 month , new symptom associate diabetes previous 3 month . Have score &gt; 2 point Michigan Neuropathy Screening Instrument ( MNSI ) , part Bphysical assessment health professional . Have ECG without clinically significant abnormality . The following inclusion criterion ascertain baseline visit : Have measurable pain perception ( previous 24h ) Likert numerical rating scale mean≥4.0 point calculate least 4 daily measurement 7 day immediately prior Baseline Visit . Have stop current pain medication least 14 day prior Baseline Visit ( except rescue medication ) . Be pregnant female , lactate female , female child bear potential ( ≤60 year age ) . Have document neuropathy cause mention inclusion criterion might interfere assessment severity pain ( eg , include , limited , alcoholic , uremic , B12 , TSH , chemotherapy , HIV , post surgical , posttraumatic neuropathy ) . Have neurological disease may produce weakness , sensory loss , autonomic symptom , laboratory test abnormality . Have pain treatment strong opioids , 4 different drug regimen previous year , current combination 2 drug . Have current medication lipid lower agent statin . Have body mass index ( BMI ) &gt; 40 kg/m2 ( obesity grade III ) . Had surgery within previous 2 month . Have concurrent serious neurological disease ( eg , dementia , multiple sclerosis , disease would impact ability patient provide consent study participation ) . Have recent history ( within previous 6 month ) current evidence alcohol drug abuse . Have concurrent unstable disease involve system ( eg , advanced carcinoma , myocardial infarction , clinical ECG sign myocardial ischemia , cardiac insufficiency i.e.≥ NYHA functional classification class 2 , anginal symptom , current symptom CAD , renal impairment , condition opinion Investigator would make patient unsuitable study participation ) . Participated investigational drug therapy study within previous 3 month . Changed interrupt current welltolerated medication previous 3 month . Lack ability willingness give inform consent . Be possibly dependent Investigator Sponsor ( eg , include , limited , affiliated employee ) . Have hemostasis disorder current treatment anticoagulant . Have nonadequate renal and/or hepatic function follow : Renal Blood creatinine &gt; 1.5X upper limit normal ( ULN ) Hepatic Liver enzymes ( ALT AST ) &gt; 2 X ULN Have know history current cardiac dysrhythmias / know history current cardiovascular disease include myocardial infarction except patient well control hypertension . Are able comply regard known contraindication , warning precaution , druginteractions dose recommendation paracetamol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetic Neuropathy</keyword>
	<keyword>Painful Peripheral Diabetic Neuropathy</keyword>
	<keyword>TRO19622</keyword>
	<keyword>Trophos</keyword>
</DOC>